Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

• To observe the visual changes in PCV patients receiving Conbercept treatment, so as to evaluate the effectiveness of the treatment. Changes of OCT, ICGA, quality of life and visual function would be observed and evaluated.
• To observe and describe the characteristics of PCV.
• To observe and describe the incidence of adverse events (AE) and serious adverse events (SAE) of Conbercept in the treatment of PCV, so as to evaluate the safety of this treatment.
• To observe and descirbe the real situation and prognosis of PCV patients in our country.

Inclusion criteria

• According to the current diagnostic criteria, diagnosed as PCV patients
• Conbercept is used for treatment, and the recommended treatment scheme is 3+PRN
• Local and systemic anti-VEGF therapy was not used for at least three months before enrollment
• The patient volunteers to take part in this observational study, and signs the informed consent
• The patient can follow-up regularly (at least 4 times of follow-up in one year)

Exclusion criteria

• The patient has serious systemic disease, and the current clinical treatment is contraindicated
• Local or systemic anti-VEGF therapy was used for less than three months before enrollment
• Existence of diseases unsuitable to accept intravitreal Conbercept, including uncontrolled hypertension and diabetes, AIDS, malignant tumors, active hepatitis, severe renal failure, severe mental, nerve, cardiovascular, respiratory and immune diseases
• During six months before screening, there were cardiovascular events such as stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure
• Ocular contraindications, including active intraocular inflammation, infectious endophthalmitis, corneal ulcer, scleritis, uncontrolled glaucoma and so on
• Patients who could not follow up regularly
• Patients who refuse to sign the informed consent
• Others